{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:50:03Z","timestamp":1778525403362,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.taap.2017.03.016","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T17:18:57Z","timestamp":1489857537000},"page":"36-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs"],"prefix":"10.1016","volume":"323","author":[{"given":"Hai","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-5629","authenticated-orcid":false,"given":"Xunlong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2017.03.016_bb0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van Bommel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.03.016_bb0010","first-page":"5153","article-title":"Synergistic effect of a noveloxymatrine-baicalin combination against hepatitis B virus replication, alpha smooth muscle actin expression and type I collagen synthesis in vitro","volume":"12","author":"Cheng","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.taap.2017.03.016_bb0015","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.13150","article-title":"Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B","volume":"41","author":"Chi","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2017.03.016_bb0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.09.011","article-title":"Hepatitis B virus reverse transcriptase-target of current antiviral therapy and future drug development","volume":"123","author":"Clark","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0025","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1093\/nar\/gku260","article-title":"Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1\u03b1","volume":"42","author":"Dai","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2017.03.016_bb0030","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.03.016_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpe at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0045","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1128\/JVI.03094-14","article-title":"Inhibition of hepatitis B virus gene expression and replication by hepatocyte nuclear factor 6","volume":"89","author":"Hao","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.taap.2017.03.016_bb0050","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.18632\/oncotarget.7435","article-title":"ZEB2 inhibits HBV transcription and replication by targeting its core promoter","volume":"7","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2017.03.016_bb0055","doi-asserted-by":"crossref","first-page":"e30360","DOI":"10.1371\/journal.pone.0030360","article-title":"Transforming growth factor-\u03b21 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4\u03b1 expression","volume":"7","author":"Hong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2017.03.016_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","author":"Huang","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.taap.2017.03.016_bb0065","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2017.03.016_bb0070","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.03.016_bb0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2008.03.001","article-title":"In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L","volume":"79","author":"Li","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0080","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3748\/wjg.v22.i6.1943","article-title":"Hepatocellular carcinoma and hepatitis B surface protein","volume":"22","author":"Li","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.taap.2017.03.016_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2016.08.007","article-title":"Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo","volume":"134","author":"Li","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0090","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/gutjnl-2013-305785","article-title":"Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.taap.2017.03.016_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(16)00595-X","article-title":"HBV e antigen and its precursors promote the progress of HCC by interacting with NUMB and decreasing p53 activity","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.03.016_bb0100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2004.07.025","article-title":"Nitric oxide and TGF-beta 1 inhibit HNF-4 alpha function in HEPG2 cells","volume":"321","author":"de Lucas","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2017.03.016_bb0105","doi-asserted-by":"crossref","first-page":"e0142599","DOI":"10.1371\/journal.pone.0142599","article-title":"IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA Minichromosome","volume":"10","author":"Palumbo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2017.03.016_bb0110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.03.016_bb0115","first-page":"411","article-title":"Tissue-specific Forkhead protein FOXA2 up-regulates SOX14 gene expression","volume":"2010","author":"Popovic","year":"1799","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2017.03.016_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2005.07.005","article-title":"Effect of artemisinin\/artesunate as inhibitors of hepatitis B virus production in an \u201cin vitro\u201d replicative system","volume":"68","author":"Romero","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.taap.2017.03.016_bb0125","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2017.03.016_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.placenta.2006.03.009","article-title":"Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta","volume":"28","author":"Serrano","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.taap.2017.03.016_bb0135","doi-asserted-by":"crossref","first-page":"R301","DOI":"10.1186\/cc13171","article-title":"Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 infection in mice","volume":"17","author":"Shi","year":"2013","journal-title":"Crit. Care"},{"key":"10.1016\/j.taap.2017.03.016_bb0140","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/hep.28435","article-title":"Canonical NF-\u03baB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response","volume":"63","author":"Sunami","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.03.016_bb0145","doi-asserted-by":"crossref","first-page":"h4263","DOI":"10.1136\/bmj.h4263","article-title":"Management of chronic hepatitis B infection","volume":"351","author":"Sundaram","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.taap.2017.03.016_bb0150","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013:a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Vos","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2017.03.016_bb0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2011.12.045","article-title":"Estrogen receptor \u03b1 represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4\u03b1","volume":"142","author":"Wang","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2017.03.016_bb0160","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","author":"Wang","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.03.016_bb0165","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1073\/pnas.0609883104","article-title":"Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue","volume":"104","author":"Ying","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2017.03.016_bb0170","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1136\/gutjnl-2014-308943","article-title":"Towards an HBV cure: state-of-the-art and unresolved questions - report of the ANRS workshop on HBV cure","volume":"64","author":"Zeisel","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.taap.2017.03.016_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jviromet.2014.02.008","article-title":"Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus","volume":"201","author":"Zhang","year":"2014","journal-title":"J. Virol. Methods"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17301205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17301205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T07:25:49Z","timestamp":1535959549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X17301205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":35,"alternative-id":["S0041008X17301205"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2017.03.016","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2017.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}